Updates are available Correction dated 2022-06-08
Click to view Correction: https://doi.org/10.1038/s41433-022-02130-2
-
Authors
Lally, David R.
Loewenstein, Anat https://orcid.org/0000-0002-7706-1165
Arnold, Jennifer J.
Yang, Yit C. https://orcid.org/0000-0002-5392-5133
Gedif, Kinfemichael
Best, Catherine
Patel, Hersh
Tadayoni, Ramin
Heier, Jeffrey S.
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 20 September 2021
Revised: 8 April 2022
Accepted: 5 May 2022
First Online: 21 May 2022
Change Date: 8 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41433-022-02130-2
Competing interests
: DRL: Scientific advisory fees from Alimera Sciences, Allergan, Apellis, EyepointPharmaceuticals, Genentech, Iveric Bio, Novartis; research funding from Aldeyra Therapeutics,Annexon Biosciences, Apellis, Canon, Chengdu Kanghong, Emmes/MacTel Project, EyepointPharmaceuticals, Iveric Bio, Kodiak Sciences, Novartis, Neurotech, Notal Vision, Optos, StealthBiotherapeutics; AL: Consultant to Allergan, Bayer HealthCare, BeyeOnics Surgical,ForSightlabs, Notal Vision, Novartis and Roche; JJA: Honoraria from Allergan, Bayer, Alcon and Novartis; YCY: Receipt of honoraria, travel reimbursement, patent royalties from Alcon, Allergan, Alimera Sciences, Bayer, Novartis, Pfizer, Thrombogenics, Heidelberg and Roche; KG: Employee of Novartis Pharmaceuticals Corporation, Fort Worth, TX, USA; CB: Employee of Novartis Pharma AG, Switzerland; HP: Former employee of Novartis Pharmaceuticals Corporation, East Hannover, NJ, USA; RT: Alcon, Bausch and Lomb, FCI, Moria, Zeiss, Optovue, Topcon, Alimera, Allergan, Bayer, Novartis, Oculis, Genentech, Roche, Thea; JSH: Scientific advisory fees from 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Alkahest, Allegro, Allergan, Annexon, Apellis, Array, Asclepix, BVI, Eloxx, Galimedix, Genentech, Generation Bio, Gyroscope, Interface, iRenix, Janssen R&D, jCyte, Kala, Kanghong, Kodiak, NGM, Notal Vision, Novartis, Ocugenix, Oculis, Ocular Therapeutix, Omeicos, Regeneron, Regenxbio, Retrotope, Santen, Scifluor, Shire, Stealth Biotherapeutix, Tyrogenex, Voyant; research funding from Aerpio, Apellis, Clearside, Genentech, Genzyme, Gyroscope, Hemera, Janssen, jCyte, KalVista, Kanghong, Novartis, Ophthotech, Regeneron, Regenxbio, Stealth, Thrombogenics, TLC
